These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 12710193)

  • 1. Overview of novel anticancer drug targets.
    Buolamwini JK; Assefa H
    Methods Mol Med; 2003; 85():3-28. PubMed ID: 12710193
    [No Abstract]   [Full Text] [Related]  

  • 2. Restoration of wild-type p53 function in human tumors: strategies for efficient cancer therapy.
    Wiman KG
    Adv Cancer Res; 2007; 97():321-38. PubMed ID: 17419952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
    Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
    J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Responses to targeted therapies: lung cancer].
    Brambilla E
    Ann Pathol; 2009 Nov; 29 Spec No 1():S77-80. PubMed ID: 19887261
    [No Abstract]   [Full Text] [Related]  

  • 5. Targeted cancer therapy: promise and reality.
    Klein S; Levitzki A
    Adv Cancer Res; 2007; 97():295-319. PubMed ID: 17419951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New targets for non-small-cell lung cancer therapy.
    Alvarez M; Roman E; Santos ES; Raez LE
    Expert Rev Anticancer Ther; 2007 Oct; 7(10):1423-37. PubMed ID: 17944567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Farnesyl transferase inhibitors.
    Li T; Sparano JA
    Cancer Invest; 2008 Aug; 26(7):653-61. PubMed ID: 18665473
    [No Abstract]   [Full Text] [Related]  

  • 8. Anti-tumor activity of phenoxodiol: from bench to clinic.
    Alvero AB; Kelly M; Rossi P; Leiser A; Brown D; Rutherford T; Mor G
    Future Oncol; 2008 Aug; 4(4):475-82. PubMed ID: 18684059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New agents for prostate cancer.
    Reese DM
    Hematol Oncol Clin North Am; 2001 Jun; 15(3):547-57. PubMed ID: 11525296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A rationally designed small molecule that inhibits the HIF-1alpha-ARNT heterodimer from binding to DNA in vivo.
    Vinson C
    Sci STKE; 2005 May; 2005(284):pe23. PubMed ID: 15900031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological inhibitors of the ERK signaling pathway: application as anticancer drugs.
    Kohno M; Pouyssegur J
    Prog Cell Cycle Res; 2003; 5():219-24. PubMed ID: 14593716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches.
    Eberle J; Kurbanov BM; Hossini AM; Trefzer U; Fecker LF
    Drug Resist Updat; 2007 Dec; 10(6):218-34. PubMed ID: 18054518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Applicability of coexpression networks analysis to anticancer drug targets discovery].
    Ivliev AE; Rudneva VA; Sergeeva MG
    Mol Biol (Mosk); 2010; 44(2):366-74. PubMed ID: 20586197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New agents in the treatment of acute myeloid leukemia: a snapshot of signal transduction modulation.
    Bao T; Smith BD; Karp JE
    Clin Adv Hematol Oncol; 2005 Apr; 3(4):287-96, 302. PubMed ID: 16167001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 7-Chloro-6-piperidin-1-yl-quinoline-5,8-dione (PT-262), a novel synthetic compound induces lung carcinoma cell death associated with inhibiting ERK and CDC2 phosphorylation via a p53-independent pathway.
    Hsu TS; Chen C; Lee PT; Chiu SJ; Liu HF; Tsai CC; Chao JI
    Cancer Chemother Pharmacol; 2008 Oct; 62(5):799-808. PubMed ID: 18193228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Methods for the preclinical screening of new anticancer agents].
    Debussche L
    Bull Cancer; 2001 Jan; 88(1):67-74. PubMed ID: 11182655
    [No Abstract]   [Full Text] [Related]  

  • 17. Rational targeting of Notch signaling in cancer.
    Rizzo P; Osipo C; Foreman K; Golde T; Osborne B; Miele L
    Oncogene; 2008 Sep; 27(38):5124-31. PubMed ID: 18758481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
    Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
    Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase inhibitors: multifunctional anticancer agents.
    Liu T; Kuljaca S; Tee A; Marshall GM
    Cancer Treat Rev; 2006 May; 32(3):157-65. PubMed ID: 16516391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue factor in cancer and angiogenesis: the molecular link between genetic tumor progression, tumor neovascularization, and cancer coagulopathy.
    Rak J; Milsom C; May L; Klement P; Yu J
    Semin Thromb Hemost; 2006 Feb; 32(1):54-70. PubMed ID: 16479463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.